Metformina + Sitagliptina Farmoz

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metformina + Sitagliptina Farmoz, are a biguanide and a DPP‑4 inhibitor presented as oral tablets for oral use. The combination leverages complementary mechanisms to lower hepatic glucose output and enhance insulin secretion. They treat type 2 diabetes mellitus in adult patients by improving blood glucose control.

GNH USA supplies Metformina + Sitagliptina Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing high‑quality generic medicines that meet European Union standards.

Metformina + Sitagliptina Farmoz is used in the management of type 2 diabetes mellitus, targeting glucose regulation.

- Type 2 diabetes mellitus: improves overall glycemic control when added to diet, exercise and existing therapy. - Inadequate control on metformin alone: provides additional glucose‑lowering effect as adjunct therapy. - Inadequate control on sitagliptin alone: offers combined action to enhance insulin secretion and reduce hepatic glucose production.

Metformina + Sitagliptina Farmoz may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic condition. - Severe hypoglycemia: especially when combined with other glucose‑lowering agents. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Hepatotoxicity: liver enzyme elevations or injury. - Allergic reactions: rash, itching, or angioedema.

Before prescribing Metformina + Sitagliptina Farmoz, clinicians should consider several safety considerations. - Renal function: assess creatinine clearance; dose adjustment may be needed in impairment. - Hepatic disease: use cautiously in patients with liver dysfunction. - Cardiovascular status: monitor for heart failure, especially with metformin. - Risk of hypoglycemia: educate patients when used with insulin or sulfonylureas. - Pregnancy and lactation: avoid unless benefits outweigh risks; consult guidelines. - Store at ambient temperature: keep below 25°C in original container, protect from moisture.

Metformina + Sitagliptina Farmoz can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; withhold metformin before and after imaging. - Strong CYP3A4 inhibitors: increase sitagliptin plasma levels, raising risk of adverse effects. - Insulin or sulfonylureas: potentiate hypoglycemia; dose adjustments required.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors/ARBs: combined use may impact renal function. - Corticosteroids: can raise blood glucose, reducing drug effectiveness. - Alcohol: can increase risk of lactic acidosis with metformin.